Sydbank positive despite muted growth for Darzalex
Partner J&J's interim report shows that sales of Genmab’s cancer drug Darzalex doubled in Q3. However, the growth rate is lower compared to earlier this year, whivh has caused a drop in Genmab's share price. But despite the cancer hope’s failure to meet expectations, Sydbank still calls the development positive.
BY ELIZABETH MØNSTED JOHANSEN AND RITZAU FINANS
Genmab’s multiple myeloma drug Darzalex, to which Johnson & Johnson holds the exclusive rights, is still doing well on the market. Johnson & Johnson’s Q3 interim report shows that sales of Darzalex have almost doubled compared to the same period last year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Japan approves Genmab cancer drug
For abonnenter
Darzalex is still the “star of the show” for Genmab
For abonnenter
Genmab’s cash cow obtains new approval
For abonnenter
